Calling all radiation oncologists! Complete the Radiation Oncologist Job Satisfaction Survey The survey attempts to gain insight into what factors most strongly influence radiation oncologist job fulfillment and identify opportunities for strategic improvement for our specialty.

🤔Ever thought about delivering SBRT to a prostate in someone with an ileo-anal anastomosis? In this teaching case, an unfavorable intermediate risk prostate cancer was treated with ✅SBRT to 35 Gy in 5 fractions ✅no rectal spacer ✅6 months of neoadjuvant ADT So far, at 23

How do #radonc residents and attendings view education on evaluating☢️ tx plans (RTPs)? In this multi-institutional survey of RTP evaluation practices, residents (R, n=72) and attendings (A, n=20) held some different ❌perspectives: 🔘93% of R completed 3+ contours per wk, w/

Let's talk about 💩during radiation! In 83 patients with locally advanced cervical cancer, 💩stool samples at baseline, week 4, and week 8 underwent 16S rRNA sequencing to map 🧫microbial diversity + identify which 🦠bacteria were rising or falling during treatment. 🔬 Week 4

Happy Thanksgiving! We are immensely thankful for our editors, reviewers, readers, and everyone else along the way! Thank you for making Advances great and pushing the envelope in #radonc

How do rectal and urinary side effects differ between #pcsm pts treated w/ and w/o rectal spacer? In this institutional series of pt w/ low-int risk PCa receiving SBRT (32.5-40 Gy in 5 fx), ☢️ was delivered w/ (n=227) and w/o (n=75) hydrogel spacer 🔘Btwn groups: age, prostate

Meta-analysis: Among patients with intermediate-, high-, or very high-risk prostate cancer, the ideal duration of ADT with radiotherapy demonstrated nonlinear benefits, with diminished gains after 12 months and variation in benefit by risk group. https://t.co/corNHgWM5b

Ever thought about 🔄️re-irradiation for squamous cell carcinoma of the anal canal? Turns out... it can be done! Thanks to this ⏪retrospective study of 35 patients by @jordan_McD3 @ThatDamDoc @PrajnanDasMD @eugenekoay @ebludmir @Snoticewala @VanMorrisMD @DrEmmaHolliday

What is the impact of fractionated SRS (fSRS) for large (3-6cm) 🧠mets on neurocog function? In this single institution phase I study of fSRS, 15/24 enrolled pts completed neurocog assessments at baseline and 4mo post ☢️: 🔘Clinical + tx characteristics (median): 57 yo, KPS 80,

❓Preoperative radiation for abdominopelvic soft-tissue sarcomas often exceeds traditional bowel dose constraints—but what does that actually mean for patients? In this retrospective cohort of 76 patients (median follow-up 46 months) from @MDAndersonNews : ☑️68% exceeded ≥1

What is the rate of ☢️-inducted hypopituitarism (RIH) after stereotactic RT for sellar/peri-sellar skull base tumors? In this institutional series of patients w/ sellar/peri-sellar meningiomas (n=46) or pituitary adenomas (n=20) receiving ☢️ 🔘In mFU 83.5 mo ➡️ 10.7% (n=6)

🚨Practice affirming results!🚨 The #radonc docs @UCSDRadMed @UCSDRadRes tried to answer the age-old question of... ��What is considered a high-risk biochemical recurrence (BCR) after RT to the prostate❓ Is it pre-RT PSA, stage, grade? Is it post-RT PSA doubling time? Turns

How can we enhance the effect of SBRT ☢️ for unresectable liver tumors (HCC or mets)? This Ph I study examined intratumoral injection of NBTXR3 (a nanoparticle radioenhancer) at 5 dose levels (ranging form 10-43% of GTV volume) followed by SBRT (45/3 or 50/5) ➡️ 🔘 During tx G3

We use some 👻🎃scary high🧙‍♀️☠️radiation doses when treating trigeminal neuralgia (TN) to reduce those pain ⚡️jolts! @janeJomy & team conducted this systemic review and meta-analysis of 8 publications including close to 2,600 patients! They found: ✅higher dose rate➡️higher pain

What factors are associated w/ prophylactic (pGT) vs reactive (rGT) G-tube placement in pts receiving (chemo)RT for #hncsm? In this institutional series (n=202), pts had primarily oropharynx cancer (51%) and Stage III-IV disease (55%) ➡️ received definitive ☢️ (64%) - mean 67

@Advances_ASTRO @UTSW_RadOnc @RadoncUsc This study conducted utsw/usc by Drs Lock, Soni and Leslie Ballas with med/onc @TiansterZhang demonstrated no increased toxicity signal by the combo with RT/ADC toxicity primarily reflecting expected ADC toxicity. Of import on heels of impressive ADC/IO data at esmo2025 in mUC

Thinking about delivering radiation for urothelial carcinoma but not sure if its safe 🛟with antibody drug conjugates (ADCs, like enfortumab vedotin & sacituzumab)? In this ⏪retrospective review by @ndesai2005 & colleagues from @UTSW_RadOnc ➕ @RadoncUsc, 166 courses of RT were

What is the utility of ctDNA 🧬🩸 testing in Merkel cell carcinoma (MCC)? In this institutional series, pts (n=48) w/ Stage I-III MCC treated w/ ☢️alone had ctDNA tested before, during, & after tx 🔘 18/20 pts cleared ctDNA during ☢️and were disease free at FU ➡️ NPV = 90% 🔘

On behalf of @RachelJimenezMD and the entire Editorial Board at Advances, we would like to welcome two new members to the team! Jan Kriz, MD, PhD, Chair of Radiation Oncology at Clemens Hospital in Muenster, Germany will be Section Editor of our ✨new✨benign/palliative

What factors are associated with ❤️ disease in #bcsm pts getting ☢️? In this series (n=174) of pts w/ Stage I-III BC and mFU 117 mo ➡️G3+ ❤️ events = 7.4% (n=13) Compared to Node- dx, Node+ dx associated with 🔘🔼 G3+❤️ events (14.2% at 10 yr) 🔘 Use of RNI, anthracyclines,